A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Public ClinicalTrials.gov record NCT03893682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Study identification
- NCT ID
- NCT03893682
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2019
- Primary completion
- May 16, 2024
- Completion
- May 16, 2024
- Last update posted
- Mar 6, 2025
2019 – 2024
United States locations
- U.S. sites
- 30
- U.S. states
- 15
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Pacific Cancer Care | Monterey | California | 93940 | — |
| Torrance Memorial Physician Network | Redondo Beach | California | 90277 | — |
| UCSD Moores Cancer Center | San Diego | California | 92093 | — |
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| Ridley-Tree Cancer Center | Santa Barbara | California | 93105 | — |
| St. Joseph Heritage Heathcare | Santa Rosa | California | 95403 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | — |
| University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| UMass Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| SCL Health, St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Manhattan Hematology Oncology | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Prisma Health - ITOR | Greenville | South Carolina | 29605 | — |
| Carolina Blood and Cancer Care Associates | Rock Hill | South Carolina | 29732 | — |
| Texas Oncology - Austin-Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| University of Texas, M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Texas Health Science Center at San Antonio, Mays Cancer Center | San Antonio | Texas | 78229 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Northwest Cancer Specialists, P.C. - Compass Oncology | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Chronic Lymphocytic Leukemia trials
Other public records listing Chronic Lymphocytic Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796373: Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Not yet recruiting
- NCT07516093: Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL Recruiting
- NCT07520006: Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies Recruiting
- NCT02048813: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting
- NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Recruiting
- NCT07734038: Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03893682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03893682 live on ClinicalTrials.gov.